trial · primary record
Nicorandil Oral Tablet
Doxorubicin Induced Cardiotoxicity
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 146 |
| Primary completion | 2027-09-01 |
| Primary endpoint | To evaluate the effect of nicorandil on left ventricular ejection fraction in breast cancer patients receiving doxorubicin. |
| Registry ID | NCT07897409 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:46.647Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07897409
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.